|
1
|
Smith RA, Cokkinides V and Brawley OW:
Cancer screening in the United States, 2012: A review of current
American Cancer Society guidelines and current issues in cancer
screening. CA Cancer J Clin. 62:129–142. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sasako M, Sakuramoto S, Katai H, Kinoshita
T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and
Ohashi Y: Five-year outcomes of a randomized phase III trial
comparing adjuvant chemotherapy with S-1 versus surgery alone in
stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sakamoto Y, Ohyama S, Yamamoto J, Yamada
K, Seki M, Ohta K, Kokudo N, Yamaguchi T, Muto T and Makuuchi M:
Surgical resection of liver metastases of gastric cancer: An
analysis of a 17-year experience with 22 patients. Surgery.
133:507–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Okuyama K, Isono K, Juan IK, Onoda S,
Ochiai T, Yamamoto Y, Koide Y and Satoh H: Evaluation of treatment
for gastric cancer with liver metastasis. Cancer. 55:2498–2505.
1985. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
D'Angelica M, Gonen M, Brennan MF,
Turnbull AD, Bains M and Karpeh MS: Patterns of initial recurrence
in completely resected gastric adenocarcinoma. Ann Surg.
240:808–816. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sakamoto Y, Sano T, Shimada K, Esaki M,
Saka M, Fukagawa T, Katai H, Kosuge T and Sasako M: Favorable
indications for hepatectomy in patients with liver metastasis from
gastric cancer. J Surg Oncol. 95:534–539. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kakeji Y, Morita M and Maehara Y:
Strategies for treating liver metastasis from gastric cancer. Surg
Today. 40:287–294. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Burton JD, Bamford RN, Peters C, Grant AJ,
Kurys G, Goldman CK, Brennan J, Roessler E and Waldmann TA: A
lymphokine, provisionally designated interleukin T and produced by
a human adult T-cell leukemia line, stimulates T-cell proliferation
and the induction of lymphokine activated killer cells. Proc Natl
Acad Sci USA. 91:4935–4939. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Grabstein KH, Eisenman J, Shanebeck K,
Rauch C, Srinivasan S, Fung V, Beers C, Richardson J, Schoenborn
MA, Ahdieh M, et al: Cloning of a T cell growth factor that
interacts with the beta chain of the interleukin-2 receptor.
Science. 264:965–968. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Perera LP: Interleukin 15: Its role in
inflammation and immunity. Arch Immunol Ther Exp (Warsz).
48:457–464. 2000.PubMed/NCBI
|
|
11
|
Di Sabatino A, Calarota SA, Vidali F,
Macdonald TT and Corazza GR: Role of IL-15 in immune-mediated
andinfectious diseases. Cytokine Growth Factor Rev. 22:19–33. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Armitage RJ, Macduff BM, Eisenman J,
Paxton R and Grabstein KH: IL-15 has stimulatory activityfor the
induction of B cell proliferation and differentiation. J Immunol.
154:483–490. 1995.PubMed/NCBI
|
|
13
|
Carson WE, Fehniger TA, Haldar S, Eckhert
K, Lindemann MJ, Lai CF, Croce CM, Baumann H and Caligiuri MA:
Apotential role for interleukin-15 in the regulation of human
natural killer cell survival. J Clin Invest. 99:937–943. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Di Santo JP, Kuhn R and Muller W: Common
cytokine receptor chain (c)-dependent cytokines: Understanding in
vivo functions by gene targeting. Immunol Rev. 148:19–34. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Asao H, Okuyama C, Kumaki S, Ishii N,
Tsuchiya S, Foster D and Sugamura K: Cutting edge: The common
-chain is an indispensable subunit of the IL-21 receptor complex. J
Immunol. 167:1–5. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Davies E, Reid S, Medina MF, Lichty B and
Ashkar AA: IL-15 has innate anti-tumor activity independent of NK
and CD8 T cells. J Leukoc Biol. 88:529–536. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oh S, Berzofsky JA, Burke DS, Waldmann TA
and Perera LP: Coadministration of HIV vaccine vectors with
vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting
cellular immunity. Proc Natl Acad Sci USA. 100:3392–3397. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Munger W, DeJoy SQ, Jeyaseelan R Sr,
Torley LW, Grabstein KH, Eisenmann J, Paxton R, Cox T, Wick MM and
Kerwar SS: Studies evaluating the antitumor activity and toxicity
of interleukin-15, a new T cell growth factor: Comparison with
interleukin-2. Cell Immunol. 165:289–293. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Steel JC, Waldmann TA and Morris JC:
Interleukin-15 biology and its therapeutic implications in cancer.
Trends Pharmacol Sci. 33:35–41. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Paget S: The distribution of secondary
growths in cancer of the breast. Cancer Metastasis Rev. 8:98–101.
1889.
|
|
21
|
Giri JG, Ahdieh M, Eisenman J, Shanebeck
K, Grabstein K, Kumaki S, Namen A, Park LS, Cosman D and Anderson
D: Utilization of the beta and gamma chains of the IL-2 receptor by
the novel cytokine IL-15. EMBO J. 13:2822–2830. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
D¨obbeling U, Dummer R, Laine E, Potoczna
N, Qin JZ and Burg G: Interleukin-15 is an autocrine/paracrine
viability factor for cutaneous T-cell lymphoma cells. Blood.
92:252–258. 1998.PubMed/NCBI
|
|
23
|
Heemskerk B, Liu K, Dudley ME, Johnson LA,
Kaiser A, Downey S, Zheng Z, Shelton TE, Matsuda K, Robbins PF, et
al: Adoptive cell therapy for patients with melanoma, using
tumor-infiltrating lymphocytes genetically engineered to secrete
interleukin-2. Hum Gene Ther. 19:496–510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Klapper JA, Downey SG, Smith FO, Yang JC,
Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM and
Rosenberg S: High-dose interleukin-2 for the treatment of
metastatic renal cell carcinoma: A retrospective analysis of
response and survival in patients treated in the surgery branch at
the National Cancer Institute between 1986 and 2006. Cancer.
113:293–301. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Schwartz RN, Stover L and Dutcher J:
Managing toxicities of high-dose interleukin-2. Oncology (Williston
Park). 16 11 Suppl 13:S11–S20. 2002.
|
|
26
|
Sheng YQ, Cui LX, He W, Xue L and Ba DN:
Antitumor effects of human IL-15 gene modified lung cancer cell
line. Chin J Cancer Res. 9:240–244. 1997. View Article : Google Scholar
|
|
27
|
Xia H, Luo LM, Wen JX and Tong WC:
Inhibitory effects of recombinant human endostatin on growth and
metastasis of lung adenocarcinoma LA795 in mice. Ai Zheng.
21:1197–1202. 2002.(In Chinese). PubMed/NCBI
|
|
28
|
Lasek W, Basak G, Switaj T, Jakubowska AB,
Wysocki PJ, Mackiewicz A, Drela N, Jalili A, Kamiński R, Kozar K
and Jakóbisiak M: Complete tumor regressions induced by vaccination
with IL-12 gene-transduced tumor cells in combination with IL-15 in
a melanoma model in mice. Cancer Immunol Immunother. 53:363–372.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sabbagh L, Snell LM and Watts TH: TNF
family ligands define niches for T cell memory. Trends Immunol.
28:333–339. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chapoval AI, Fuller JA, Kremlev SG, Kamdar
SJ and Evans R: Combination chemotherapy and IL-15 administration
induce permanent tumor regression in a mouse lung tumor model: NK
and T cell-mediated effects antagonized by B cells. J Immunol.
161:6977–6984. 1998.PubMed/NCBI
|
|
31
|
Zhang M, Yao Z, Dubois S, Ju W, Müller JR
and Waldmann TA: Waldmann: Interleukin-15 combined with an
anti-CD40 antibody provides enhanced therapeutic efficacy for
murine models of colon cancer. Proc Natl Acad Sci USA.
106:7513–7518. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu P, Steel JC, Zhang M, Morris JC and
Waldmann TA: Simultaneous blockade of multiple immune system
inhibitory checkpoints enhances antitumor activity mediated by
interleukin-15 in a murine metastatic colon carcinoma model. Clin
Cancer Res. 16:6019–6028. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Okano K, Maeba T, Ishimura K, Karasawa Y,
Goda F, Wakabayashi H, Usuki H and Maeta H: Hepatic resection for
metastatic tumors from gastric cancer. Ann Surg. 235:86–91. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kennedy MK, Glaccum M, Brown SN, Butz EA,
Viney JL, Embers M, Matsuki N, Charrier K, Sedger L, Willis CR, et
al: Reversible defects in natural killer and memory CD8 T cell
lineages in interleukin 15-deficient mice. J Exp Med. 191:771–780.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lodolce JP, Boone DL, Chai S, Swain RE,
Dassopoulos T, Trettin S and Ma A: IL-15 receptor maintains
lymphoid homeostasis by supporting lymphocyte homing and
proliferation. Immunity. 9:669–676. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Becknell B and Caligiuri MA:
Interleukin-2, interleukin-15, and their roles in human natural
killer cells. Adv Immunol. 86:209–239. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jiang X, Chen Y, Peng H and Tian Z: Memory
NK cells: Why do they reside in the liver? Cell Mol Immunol.
10:196–201. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Minagawa M, Watanabe H, Miyaji C, Tomiyama
K, Shimura H, Ito A, Ito M, Domen J, Weissman IL and Kawai K:
Enforced expression of Bcl-2 restores the number of NK cells, but
does not rescue the impaired development of NKTcells or
intraepithelial lymphocytes, in IL-2/IL-15 receptor
beta-chain-deficient mice. J Immunol. 169:4153–4160. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Koka R, Burkett P, Chien M, Chai S, Boone
DL and Ma A: Cutting edge: Murine dendritic cells require
IL-15Ralpha to prime NK cells. J Immunol. 173:3594–3598. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Castillo EF and Schluns KS: Regulating the
Immune system via IL-15 Transpresentation. Cytokine. 59:479–490.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Budhu A, Forgues M, Ye QH, Jia HL, He P,
Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY and Wang XW:
Prediction of venous metastases, recurrence, and prognosis in
hepatocellular carcinoma based on a unique immune response
signature of the liver microenvironment. Cancer Cell. 10:99–111.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Muller AJ and Scherle PA: Targeting the
mechanisms of tumoral immune tolerance with small-molecule
inhibitors. Nat Rev Cancer. 6:613–625. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hammerstrom AE, Cauley DH, Atkinson BJ and
Sharma P: Cancer immunotherapy: Sipuleucel-T and beyond.
Pharmacotherapy. 31:813–828. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cheson BD and Leonard JP: Monoclonal
antibody therapy for B-cell non-Hodgkin 7S lymphoma. N Engl J Med.
359:613–626. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ljunggren HG and Malmberg KJ: Prospects
for the use of NK cells in immunotherapy of human cancer. Nat Rev
Immunol. 7:329–339. 2007. View Article : Google Scholar : PubMed/NCBI
|
